PDL BioPharma Stock Forecast, Price & News

PDL BioPharma's stock was trading at $3.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PDLI shares have decreased by 26.4% and is now trading at $2.26.
View which stocks have been most impacted by COVID-19.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for PDL BioPharma.

PDL BioPharma is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for PDL BioPharma.

PDL BioPharma, Inc. (NASDAQ:PDLI) released its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.10 by $0.53. The biotechnology company had revenue of $5.21 million for the quarter.
View PDL BioPharma's earnings history.

PDL BioPharma announced a quarterly dividend on Thursday, September 10th. Investors of record on Tuesday, September 22nd will be given a dividend of $0.076 per share on Thursday, October 1st. This represents a $0.30 dividend on an annualized basis and a yield of 13.45%. The ex-dividend date is Monday, September 21st. This is a boost from PDL BioPharma's previous quarterly dividend of $0.05.
View PDL BioPharma's dividend history.

1 brokers have issued 1-year target prices for PDL BioPharma's stock. Their forecasts range from $3.00 to $3.00. On average, they expect PDL BioPharma's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 32.7% from the stock's current price.
View analysts' price targets for PDL BioPharma.

PDL BioPharma saw a decrease in short interest in September. As of September 30th, there was short interest totaling 9,850,000 shares, a decrease of 24.8% from the September 15th total of 13,100,000 shares. Based on an average daily trading volume, of 1,100,000 shares, the days-to-cover ratio is presently 9.0 days. Approximately 9.0% of the shares of the stock are sold short.
View PDL BioPharma's Short Interest.

Some companies that are related to PDL BioPharma include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include AT&T (T), Opko Health (OPK), Canopy Growth (CGC), Advanced Micro Devices (AMD), Novavax (NVAX), General Electric (GE), Teva Pharmaceutical Industries (TEVA), Bank of America (BAC), Bausch Health Companies (BHC) and Cara Therapeutics (CARA).

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

PDL BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Bellecapital International Ltd. (0.09%), Deltec Asset Management LLC (0.04%) and Nisa Investment Advisors LLC (0.01%).
View institutional ownership trends for PDL BioPharma.

PDLI stock was purchased by a variety of institutional investors in the last quarter, including Bellecapital International Ltd., Deltec Asset Management LLC, and Nisa Investment Advisors LLC.
View insider buying and selling activity for PDL BioPharma.

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PDLI stock can currently be purchased for approximately $2.26.

PDL BioPharma has a market capitalization of $257.59 million and generates $54.76 million in revenue each year. The biotechnology company earns $-70,410,000.00 in net income (profit) each year or $0.28 on an earnings per share basis. PDL BioPharma employs 109 workers across the globe.

The official website for PDL BioPharma is www.pdl.com.

PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]